This fermented soy enzyme dissolves 95% of arterial plaque in clinical trials
A groundbreaking clinical trial reveals that consuming 10,800 fibrinolysis units of nattokinase daily can reduce arterial plaque by up to 95.4% and significantly lower cardiovascular disease risk. This fermented soy enzyme, derived from traditional Japanese natto, is proving to be a powerful natural alternative to conventional blood thinners and cholesterol medications. The science behind fermented … Lire plus